Supplemental Figure 3 from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring

Supplemental Figure S3. A. Waterfall plot based on RECIL criteria. RECIL introduces the minimal response category which is a 10-30% reduction in the sum of longest diameters of target lesions. B. Event-free survival Kaplan-Meier curve.